April 9, 2013
/PRNewswire/ - In view of the annual and special meeting of its shareholders on
April 29, 2013
, DiagnoCure Inc. (TSX: CUR; OTCQX: DGCRF) (the "Corporation") announces the adoption by its board of directors of an advance notice policy establishing conditions and framework to submit director nominations, similar to what is set forth in the advance notice by-law adopted on
March 11, 2013
The advance notice by-law, which is fully described in the management proxy circular filed on
March 26, 2013
under the Corporation's profile at
, requires advance notice to the Corporation in circumstances where nominations of persons for election as a director of the Corporation are made by shareholders other than pursuant to: (i) a requisition of a meeting made pursuant to the provisions of the
Business Corporations Act
); or (ii) a shareholder proposal made pursuant to the provisions of this same act. Among other things, the advance notice by-law fixes a deadline by which shareholders must submit a notice of director nominations to the Corporation prior to any annual or special meeting of shareholders where directors are to be elected and sets forth the information that a shareholder must include in the notice for it to be valid.
As an interim and special procedure before ratification of the advance notice by-law by the shareholders, the policy stipulates that an advance notice regarding nominations of directors will have to be sent to the Corporation not less than 10 days prior to the upcoming meeting of
April 29, 2013
, i.e. by
April 18, 2013
at the latest (rather than the 30 to 65 days prior to the date of the meeting required by the advance notice by-law). All the other provisions of the advance notice by-law which are described in the management proxy circular and available under the Company's profile at
apply under the policy.
The policy on the advance notice is effective immediately. At the next meeting of shareholders, shareholders will be asked to confirm and ratify the advance notice by-law.